Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial (vol 399, pg 1779, 2022)

被引：0
|
作者：
Delany-Moretlwe, S.
Hughes, J. P.
Bock, P.
机构：
来源：
LANCET | 2022年 / 399卷 / 10337期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1778 / 1778
页数：1
相关论文
共 50 条
  • [41] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial (vol 19, pg 295, 2018)
    de Boer, S. M.
    Powell, M. E.
    Mileshkin, L.
    [J]. LANCET ONCOLOGY, 2018, 19 (04): : E184 - E184
  • [42] Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID) : 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial (vol 4, e284, 2017)
    Aberg, J. A.
    Sponseller, C. A.
    Ward, D. J.
    [J]. LANCET HIV, 2017, 4 (07): : E283 - E283
  • [43] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
    Overton, Edgar T.
    Richmond, Gary
    Rizzardini, Giuliano
    Jaeger, Hans
    Orrell, Catherine
    Nagimova, Firaya
    Bredeek, Fritz
    Deltoro, Miguel Garcia
    Swindells, Susan
    Andrade-Villanueva, Jaime Federico
    Wong, Alexander
    Khuong-Josses, Marie-Aude
    Van Solingen-Ristea, Rodica
    van Eygen, Veerle
    Crauwels, Herta
    Ford, Susan
    Talarico, Christine
    Benn, Paul
    Wang, Yuanyuan
    Hudson, Krischan J.
    Chounta, Vasiliki
    Cutrell, Amy
    Patel, Parul
    Shaefer, Mark
    Margolis, David A.
    Smith, Kimberly Y.
    Vanveggel, Simon
    Spreen, William
    [J]. LANCET, 2020, 396 (10267): : 1994 - 2005
  • [44] GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol) (vol 14, pg 1, 2022)
    Conduit, C.
    Mak, B.
    Qu, W.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [45] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
    Jaeger, Hans
    Overton, Edgar
    Richmond, Gary
    Rizzardini, Giuliano
    Andrade-Villanueva, Jaime Federico
    Mngqibisa, Rosie
    Hermida, Antonio Ocampo
    Thalme, Anders
    Belonosova, Elena
    Ajana, Faiza
    Benn, Paul D.
    Wang, Yuanyuan
    Hudson, Krischan J.
    Espanol, Carlos Martin
    Ford, Susan L.
    Crauwels, Herta
    Margolis, David A.
    Talarico, Christine L.
    Smith, Kimberly Y.
    van Eygen, Veerle
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Spreen, William R.
    [J]. LANCET HIV, 2021, 8 (11): : E679 - E689
  • [46] Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies (vol 391, pg 839, 2018)
    Llibre, J. M.
    Hung, C-C
    Brinson, C.
    [J]. LANCET, 2018, 391 (10138): : 2416 - 2416
  • [47] Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial (vol 402, pg 859, 2023)
    Lafayette, R.
    Kristensen, J.
    Stone, A.
    [J]. LANCET, 2023, 402 (10405): : 850 - 850
  • [48] Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (vol 14, pg 552, 2013)
    Motzer, R. J.
    Escudier, B.
    Tomczak, P.
    [J]. LANCET ONCOLOGY, 2013, 14 (07): : E254 - E254
  • [49] Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial (vol 4, e000723, 2018)
    Mease, P. J.
    Kavanaugh, A.
    Reimold, A.
    [J]. RMD OPEN, 2018, 4 (02):
  • [50] Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial
    Baeten, Jared M.
    Donnell, Deborah
    Mugo, Nelly R.
    Ndase, Patrick
    Thomas, Katherine K.
    Campbell, James D.
    Wangisi, Jonathan
    Tappero, Jordan W.
    Bukusi, Elizabeth A.
    Cohen, Craig R.
    Katabira, Elly
    Ronald, Allan
    Tumwesigye, Elioda
    Were, Edwin
    Fife, Kenneth H.
    Kiarie, James
    Farquhar, Carey
    John-Stewart, Grace
    Kidoguchi, Lara
    Coombs, Robert W.
    Hendrix, Craig
    Marzinke, Mark A.
    Frenkel, Lisa
    Haberer, Jessica E.
    Bangsberg, David
    Celum, Connie
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (11): : 1055 - 1064
12345